BiotechTube

LITFULO

Pre-clinicalActive
0 watching 0 views this week💤 Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alopecia Areata

Conditions

Alopecia Areata

Trial Timeline

Mar 1, 2024 → Apr 24, 2030

NCT ID
NCT06279221

About LITFULO

LITFULO is a pre-clinical stage product being developed by Pfizer for Alopecia Areata. The current trial status is active. This product is registered under clinical trial identifier NCT06279221. Target conditions include Alopecia Areata.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (2)

NCT IDPhaseStatus
NCT07152119Pre-clinicalRecruiting
NCT06279221Pre-clinicalActive

Competing Products

20 competing products in Alopecia Areata

See all competitors
ProductCompanyStageHype Score
BaricitinibEli LillyPhase 2
52
CTP-543Sun PharmaceuticalPhase 2/3
65
CTP-543Sun PharmaceuticalPhase 3
77
Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2/3
65
Baricitinib 4 MG Oral TabletEli LillyApproved
85
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
minoxidilJohnson & JohnsonPhase 3
77
5% Minoxidil + 2% MinoxidilJohnson & JohnsonPhase 3
77
Minoxidil + vehicle of 5% Minoxidil topical foamJohnson & JohnsonPhase 2
52
5% Minoxidil Topical Foam + Vehicle Topical FoamJohnson & JohnsonPhase 3
77
Upadacitinib + Upadacitinib PlaceboAbbViePhase 3
77
Upadacitinib + PlaceboAbbViePhase 3
77
Secukinumab + PlaceboNovartisPhase 2
52
DaxdilimabAmgenPhase 2
51
RitlecitinibPfizerPre-clinical
22
RitlecitinibPfizerPre-clinical
22
Ritlecitinib higher dose + Ritlecitinib lower dose + PlaceboPfizerPhase 3
76
RitlecitinibPfizerPre-clinical
22

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84